TORONTO, September 21, 2022 /PRNewswire/ — Braxia Scientific Corp. (“Braxia Scientific” or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FSE: 4960), a medical research and telemedicine company with clinics offering innovative ketamine and psilocybin treatments for depression and related disorders , is pleased to announce this LeanTaylorPresident and COO of KetaMD, Inc. (“KetaMD”), has joined the Board of Directors.
KetaMD, a telemedicine platform recently acquired by Braxia Scientific, provides access to at-home ketamine treatments for people suffering from mental disorders such as depression, bipolar disorder, anxiety and post-traumatic stress disorder (PTSD). KetaMD currently operates in the United States State of Florida but an introduction to other states is planned for this year.
About Braxia Scientific Corp.
Braxia Scientific is a medical research and telemedicine company with clinics offering innovative ketamine treatments for people living with depression and related disorders. Braxia also launched its US-based end-to-end telemedicine platform, KetaMD, which leverages leading technology to provide people living with depression and related mental illness with access to safe, affordable, and potentially life-changing ketamine treatments at home. Through its medical solutions, Braxia aims to reduce the burden of disease caused by brain-based disorders, including major depressive disorders. Braxia is primarily focused on (i) owning and operating multi-disciplinary clinics that provide in-person and virtual treatment for mental disorders, and (ii) research activities related to the discovery and commercialization of novel drugs and delivery methods. Braxia aims to develop ketamine and derivatives and other psychedelic products from its IP development platform. Through its wholly owned subsidiary, Braxia Health (formerly Canadian Rapid Treatment Center of Excellence Inc.) operates multidisciplinary community clinics providing fast-acting treatments for depression Mississauga, Toronto, Kitchener-Waterloo, Ottawaand Montreal.
ON BEHALF OF THE BOARD OF DIRECTORS
“DR Roger S McIntyre“
DR Roger S McIntyre
The CSE has not reviewed this press release and accepts no responsibility for the accuracy or adequacy of this press release.
Cautionary Statement Regarding Forward-Looking Information
This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, future estimates, plans, programs, forecasts, projections, goals, beliefs, expectations or beliefs about future performance are “forward-looking statements.”
Forward-looking statements include statements about the intended promise of ketamine-based treatments for depression, the potential of ketamine or other psychedelics to treat other mental illnesses, the integration plans for Braxia and KetaMD, the intention to conduct additional clinical trials, the anticipated growth of home telemedicine , the anticipated benefits and synergies of Braxia and KetaMD and the expectation of expanding into territories other than Florida. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results, events or developments to differ materially from any future results, events or developments expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the failure of ketamine, psilocybin and other psychedelics to provide expected health benefits and unexpected side effects, reliance on obtaining and maintaining regulatory approvals, including acquisition and renewal of federal, state, local , local or other licenses and engaging in any activity that may later be found illegal under local or international law. Ketamine and psilocybin are currently Schedule I and Schedule III controlled substances respectively under the Controlled Drugs and Substances Act, SC 1996, c. 19 (the “CDSA”) and it is a criminal offense to possess such substances under the CDSA without a prescription or legal exemption. Health Canada has not approved psilocybin for any indication as a drug, but ketamine is a legal drug to treat certain mental illnesses. It is illegal to possess such substances in Canada without a prescription.
These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements.
Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in the forward-looking statements, there may be other risk factors that could cause actions, events or results to differ materially expected. estimated or intended. Additional information identifying risks and uncertainties that could affect the financial results are contained in the Company’s filings with Canadian securities regulators, including its amended and restated listing statement dated April 15, 2021 and its most recent MD&A, which are available at www. sedar.com are available. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in the forward-looking statements.
To download multimedia, view the original content: https://www.prnewswire.com/news-releases/braxia-scientific-announces-board-appointment-301630356.html
SOURCE Braxia Scientific Corp.